Allorion Therapeutics

About Allorion Therapeutics

Allorion Therapeutics is dedicated to pioneering precision in healthcare by developing next-generation targeted drugs for human diseases. The company focuses on addressing unmet patient needs through innovative discovery platforms and a strong R&D team, while promoting commercialization through partnerships with top pharmaceutical companies.

Products & Services

Targeted Drugs:Next-generation drugs designed to address unmet medical needs for various human diseases.

Specialties

Precision Medicine Drug Development Innovative Discovery Platforms

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2023-03-09 FD: 2023-03-09	7 investors

Series B Latest

2023-03-09

$50.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Peter Ding

Chief Executive Officer

LinkedIn (Pro only)

F

Fang Li

Chief Scientific Officer

LinkedIn (Pro only)

N

Nathanael Gray

Principal Investigator

LinkedIn (Pro only)

P

Pasi Jänne

Professor

P

Pasi A. Jänne

Senior Vice President for Translational Medicine and Professor of Medicine, Harvard Medical School

K

Kwok-Kin Wong

MD, PhD, Professor of Oncology

View 4 more team members with Pro

Unlock Full Team Directory

Recent News